

A randomized controlled trial of dapagliflozin on left ventricular hypertrophy in people with type two diabetes: the DAPA-LVH trial

 academic.oup.com/eurheartj/article/doi/10.1093/eurheartj/ehaa419/5861974

Abstract

Aim

We tested the hypothesis that dapagliflozin may regress left ventricular hypertrophy (LVH) in people with type 2 diabetes (T2D).

Methods and results

We randomly assigned 66 people (mean age 67 ± 7 years, 38 males) with T2D, LVH, and controlled blood pressure (BP) to receive dapagliflozin 10 mg once daily or placebo for 12 months. Primary endpoint was change in absolute left ventricular mass (LVM), assessed by cardiac magnetic resonance imaging. In the intention-to-treat analysis, dapagliflozin significantly reduced LVM compared with placebo with an absolute mean change of -2.82g [95% confidence interval (CI): -5.13 to -0.51 , $P = 0.018$]. Additional sensitivity analysis adjusting for baseline LVM, baseline BP, weight, and systolic BP change showed the LVM change to remain statistically significant (mean change -2.92g ; 95% CI: -5.45 to -0.38 , $P = 0.025$). Dapagliflozin significantly reduced pre-specified secondary endpoints including ambulatory 24-h systolic BP ($P = 0.012$), nocturnal systolic BP ($P = 0.017$), body weight ($P < 0.001$), visceral adipose tissue (VAT) ($P < 0.001$), subcutaneous adipose tissue (SCAT) ($P = 0.001$), insulin resistance, Homeostatic Model Assessment of Insulin Resistance ($P = 0.017$), and high-sensitivity C-reactive protein (hsCRP) ($P = 0.049$).

Conclusion

Dapagliflozin treatment significantly reduced LVM in people with T2D and LVH. This reduction in LVM was accompanied by reductions in systolic BP, body weight, visceral and SCAT, insulin resistance, and hsCRP. The regression of LVM suggests dapagliflozin can initiate reverse remodelling and changes in left ventricular structure that may partly contribute to the cardio-protective effects of dapagliflozin.

ClinicalTrials.gov Identifier

NCT02956811

Introduction

Patients with type 2 diabetes (T2D) mellitus have double the risk of cardiovascular death (CVD) compared with people without T2D.^{1,2} Heart failure is an important manifestation of diabetic heart disease. Men with diabetes are twice as likely to have heart failure as those without T2D and women with T2D have a five-fold increased risk.³

Intensive management of hyperglycaemia in people with T2D using oral agents with or without insulin control reduces the risk of microvascular complications but appears to be insufficient to reduce cardiovascular (CV) events.⁴⁻⁷ However, the recent Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME) trial was a landmark trial as it demonstrated for the first time that a glucose lowering agent could reduce CV events.⁸ The most striking findings of this landmark trial were the profound early effects of the sodium-glucose cotransporter 2 inhibitor (SGLT2i), empagliflozin on CVD, and hospitalization for heart failure (HHF), which were reduced by 38% and 35%, respectively. All-cause mortality was also reduced by 32%. In the Dapagliflozin Effect on Cardiovascular Events (DECLARE TIMI 58) trial, treatment with dapagliflozin was non-inferior to placebo with respect to major adverse cardiovascular events but did result in a lower rate of the other pre-specified primary efficacy outcome (the composite of CVD or HHF) which reflected a lower rate of HHF.⁹ Significant reductions in HHF have also been reported for canagliflozin, in the Canagliflozin Cardiovascular Assessment Study (CANVAS) programme, trial.¹⁰ These consistent effects of SGLT2i glucose lowering therapy on HHF suggest the benefits may be a class effect and maybe independent of glycaemic control. This is likely to be the case since the Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction (DAPA-HF) trial recently reported that dapagliflozin significantly reduced both the incidence of CVD and worsening heart failure in patients with heart failure with reduced ejection fraction, with and without T2D.¹¹

The precise mechanisms by which SGLT2i reduces HHF are unclear but may involve natriuresis, reduction in interstitial oedema, reduced preload and afterload, improved renal function and cardio-renal physiology, inhibition of cardiac sodium-hydrogen exchange, and improved cardiac bioenergetics.¹² The potential reduction on preload and afterload could reduce left ventricular wall stress and facilitate beneficial cardiac remodelling. Cardiac remodelling can be achieved through regression of left ventricular hypertrophy (LVH). Left ventricular hypertrophy is highly prevalent amongst people with T2D with a reported prevalence of up to 70%, and the pathophysiology of LVH in T2D is not fully understood as it can develop independently of blood pressure (BP).^{13,14} The pathophysiology of LVH in T2D is complex. In addition to risk factors seen in people without T2D both obesity and associated insulin resistance are also associated with LVH in T2D.¹⁵⁻²⁰ Importantly, LVH is a strong independent predictor of CVD and CV events.^{21,22}

In this ‘proof of concept’ randomized controlled trial, we hypothesized that dapagliflozin would cause regression of left ventricular mass (LVM) in people with T2D and LVH assessed using cardiac magnetic resonance (CMR) imaging. If dapagliflozin can cause regression of LVM, we wish to try to better understand the likely mechanisms. Therefore, we also studied, as exploratory secondary outcomes, the drug’s effect on body weight and composition, BP and insulin resistance that are all potentially implicated in the pathophysiology of LVH in T2D (Supplementary material online, *Figure S1*).

Methods

The original design and methods of the DAPA-LVH trial has been published previously.²³

Study design

The DAPA-LVH study (NCT02956811) was a single-centre, double-blind, placebo-controlled trial designed to evaluate the efficacy of dapagliflozin 10 mg once daily treatment compared with placebo on LVH in participants with T2D identified to have LVH. The study was approved by the East of Scotland Research Ethics Committee (16/ES/0131) and all participants provided written informed consent to participate in the study and were enrolled in this trial for a period of 10–12 months. Supplementary material online, *Figures S2* and *S3* show the DAPA-LVH trial study design flow chart and consort diagram. Supplementary material online, *Table S1* shows all the assessments made at each trial visit.

Study participants

The study population included 66 participants recruited between February 2017 and May 2018 from Tayside, Scotland using research databases, hospital records, and local general practices.

Participants were aged 18–80 years and had been previously diagnosed with T2D based on the American Diabetes Association guidelines. Presence of LVH was defined using echocardiography as either LV mass index of $>115 \text{ g/m}^2$ for men and $>95 \text{ g/m}^2$ for women indexed to body surface area (BSA) or $>48 \text{ g/m}^{2.7}$ or $44 \text{ g/m}^{2.7}$ when indexed to height.^{2,7} People with hypertension were not excluded from the study but their clinic BP had to be $<145/90 \text{ mmHg}$ (mean value of three measurements performed at 5-min intervals on the same arm). If any individual had borderline office measurements an ambulatory BP monitor was performed to ensure BP adequately controlled. Participants had to have an HbA1c measurement within the last 6 months at screening between 48 and 85 mmol/mol. In this ‘proof of concept’

study, the primary endpoint of interest is LVM as assessed by magnetic resonance imaging (MRI). We have focused to explore this in a defined population of patients with LVH with no clinical heart failure.

Participants who met the eligibility criteria were randomly assigned to receive either dapagliflozin 10 mg once daily or matching placebo in a double-blind fashion.

Magnetic resonance imaging

Baseline and final (after a minimum of 10–12 months) MRI scans were performed on a 3T PrismaFIT MRI scanner (Siemens, Erlangen, Germany) using body array and spine matrix radiofrequency coils. Both the cardiac and abdominal MRI protocols are described in detail in Section A in the Supplementary material online. Both the cardiac and abdominal MRIs were analysed by a single-blinded observer.

Echocardiogram

The echocardiograms were done using a Phillips Epiq 7 machine. Screening for LVH was performed as per the American Society of Echocardiography (ASE) guidelines.²⁴ All the echocardiograms were performed by a single-blinded observer with British Society of Echocardiography accreditation in transthoracic echocardiography.

Laboratory investigations

Routine biochemical and haematological investigations were measured at all study visits as well as safety parameters. Biomarkers of ventricular wall stress (Amino-terminal pro B-type natriuretic peptide (NT-proBNP; Multi array, Meso Scale Discovery, Mesoscale Diagnostics, USA), oxidative stress (myeloperoxidase; R&D Systems Quantikine Human MPO Immunoassay), inflammation (high-sensitivity C-reactive protein; Kalon High-Sensitivity CRP assay), fasting Insulin (ALPCO Insulin ELISA), leptin (the R&D Systems Quantikine Human Leptin Immunoassay), and N-terminal Procollagen III peptide (Cloud Clone Procollagen III N-Terminal Propeptide competitive inhibition enzyme immunoassay) were measured at baseline and at the final visit. Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) was calculated according to the formula: $[(\text{fasting insulin (uIU/mL)} \times \text{fasting glucose (mmol/L)} \times 18)]/22.5$. Vital signs (office BP, heart rate, weight, hip, and waist circumference) were assessed at every study visit. Safety of dapagliflozin was also assessed in this patient population. All outcome parameters were measured at randomization and final visits, except safety parameters which were measured in all in-person visits.

Study endpoints

The primary endpoint was to determine whether dapagliflozin induces regression in absolute LVM assessed by cardiac MRI. The secondary endpoints were changes in LVM index (LVMI) indexed to BSA, height^{1.7} and height.^{2.7} Other exploratory secondary endpoints included changes in LV ejection fraction, LV volumes; abdominal obesity assessed by MRI; BP assessed by 24-h ambulatory measurement, weight, glycaemic parameters and blood biomarkers.

Power calculation

The power calculation of the primary outcome, absolute change in LV mass determined by cardiac MRI, was based on two previous studies.^{25,26} One study examined LVM regression in participants with ischaemic heart disease and reported that allopurinol significantly reduced LVM by -5.2 ± 5.8 g compared with placebo [-1.3 ± 4.5 g ($P < 0.007$)].²⁵ This degree of LVH regression was similar to that reported in the echo sub-study of the LIFE study.²⁷ For an 80% power at a 5% significance level ($\alpha = 0.05$), to detect a similar change in absolute LVM of 5 g, we required 29 subjects per group. To allow for a potential 10% dropout rate, the study aimed to recruit a minimum of total of 64 participants (32 per group). The 10% dropout rate is standard for such studies and includes those who withdraw consent.

Statistical analysis

The primary outcome comparison was based on intention-to-treat (ITT) analysis, i.e. all participants who had baseline measurements and took at least one dose of investigational medicinal product were analysed as part of the group to which they were randomized. Missing post-baseline values were imputed using the baseline observation carried forward method. In addition to this to provide a true estimate of the efficacy of intervention, a per-protocol analysis was also performed. The comparison between intervention and placebo groups was compared using independent samples *t*-tests for continuous variables and χ^2 test for dichotomous variables. Continuous variables with normal distribution are presented as mean (SD). Non-normally distributed data are presented as medians alongside their interquartile ranges (IQR). Additionally, we performed a sensitivity analysis using analysis of covariance (ANCOVA) model to evaluate the robustness of treatment with change in LVM and treatment as fixed effects, and baseline values for LVM, body weight, systolic blood pressure (SBP), diastolic blood pressure (DBP), and SBP change as covariates. Sensitivity analysis was also performed for the ambulatory BP measurements with the SBP change as the dependent variable and the baseline BP was the covariate and an ANCOVA was carried out. A *P*-value < 0.05 was considered significant. Data were analysed using SPSS 22.0 (IBM Corp, Armonk, NY, USA).

Results

Of the 320 participants who were screened, 66 subjects fulfilled all the study criteria and were randomly allocated to receive either dapagliflozin ($n = 32$) or placebo ($n = 34$). Supplementary material online, *Figure S3* shows the DAPA-LVH trial consort diagram.

Sixty-two participants completed the study ($n = 29$ in dapagliflozin group; $n = 33$ in placebo group). Four people withdrew from the study early; breast cancer ($n = 1$), unable to obtain holiday insurance as participating in a clinical trial ($n = 1$), hyponatraemia ($n = 1$) and claustrophobia thus unable to complete the final MRI. These people however were included in our ITT analysis.

Patient characteristics

The baseline characteristics of the participants at randomization are shown in *Tables 1 and 2*. When comparing the two groups, apart from serum potassium there were no significant differences at baseline.

Table 1
Baseline characteristics

Variable	Total cohort	Dapagliflo- zin	Placebo	P-value
Participants randomized	66	32	34	
Demographics				
Age (years)	65.53 ± 6.87	64.25 ± 7.01	66.74 ± 6.62	0.143
Male	38 (57.6%)	20 (62.5%)	18 (52.9%)	0.432
Never smoked	31 (47.0%)	14 (43.8%)	17 (50.0%)	0.611
Current smoker	4 (6.1%)	3 (9.4%)	1 (2.9%)	0.348
Ex—smoker	31 (47.0%)	15 (46.9%)	16 (47.1%)	0.988
Duration of diabetes (years) ^a	10.0 (6.0, 15.0)	8.5 (5.25, 14.5)	10.0 (7.5, 15.0)	0.343
Weight (kg)	91.53 ± 14.26	91.58 ± 14.62	91.48 ± 14.13	0.977
BMI (kg/m ²)	32.45 ± 4.41	32.30 ± 4.66	32.59 ± 4.22	0.793

Variable	Total cohort	Dapagliflo- zin	Placebo	P-value
Co-morbidities				
IHD	8 (12.1%)	2 (6.3%)	6 (17.6%)	0.260
Hypertension	51 (77.3%)	26 (81.3%)	25 (73.5%)	0.454
Stroke	7 (10.6%)	1 (3.1%)	6 (17.6%)	0.106
Hypercholesterolaemia	38 (57.6%)	17 (53.1%)	21 (61.8%)	0.478
Medications				
Ace inhibitor	35 (53.0%)	17 (53.1%)	18 (52.9%)	0.988
Angiotensin receptor blocker	11 (16.7%)	5 (15.6%)	6 (17.6%)	0.826
Calcium channel blocker	22 (33.3%)	9 (28.1%)	13 (38.2%)	0.384
Thiazide diuretic	13 (19.7%)	9 (28.1%)	4 (11.8%)	0.095
Beta-blocker	9 (13.6%)	4 (12.5%)	5 (14.7%)	0.794
Alpha-blocker	7 (10.6%)	4 (12.5%)	3 (8.8%)	0.705
Aspirin	10 (15.2%)	4 (12.5%)	6 (17.6%)	0.734
Clopidogrel	7 (10.6%)	2 (6.3%)	5 (14.7%)	0.428
Statin	55 (83.3%)	25 (78.1%)	30 (88.2%)	0.271
Metformin	66 (100.0%)	32 (100.0%)	34 (100.0%)	Constant
Sulphonylurea	15 (22.7%)	7 (21.9%)	8 (23.5%)	0.873
DDP-IV inhibitor	7 (10.6%)	4 (12.5%)	3 (8.8%)	0.705
GLP-1 agonist	7 (10.6%)	4 (12.5%)	3 (8.8%)	0.705
Thiazolidinedione	3 (4.5%)	0 (0.0%)	3 (8.8%)	0.239
Insulin	14 (21.2%)	7 (21.9%)	7 (20.6%)	0.898
Blood pressure				

Variable	Total cohort	Dapagliflo- zin	Placebo	P-value
24 h SBP baseline ^b	129.02 ± 10.09	130.41 ± 9.62	127.67 ± 10.65	0.281
	(n = 65)		(n = 33)	
24 h DBP baseline ^b	73.42 ± 7.04	74.41 ± 7.88	72.46 ± 6.09	0.267
	(n = 65)		(n = 33)	
Heart rate baseline ^c	75.31 ± 13.91	74.44 ± 13.9	76.15 ± 14.08	0.623
	(n = 65)		(n = 33)	
Daytime SBP baseline ^b	131.43 ± 10.74	132.59 ± 10.37	130.30 ± 11.19	0.394
	(n = 65)		(n = 33)	
Daytime DBP baseline ^b	75.37 ± 7.37	76.44 ± 8.57	74.33 ± 5.94	0.253
	(n = 65)		(n = 33)	
Nocturnal SBP baseline ^d	120.50 ± 12.06	123.84 ± 11.1	119.81 ± 12.8	0.183
	(n = 64)		(n = 32)	
Nocturnal DBP baseline ^d	67.50 ± 7.77	68.97 ± 7.84	66.00 ± 7.52	0.127
	(n = 64)		(n = 32)	
Office SBP baseline	136.68 ± 8.32	137.25 ± 7.5	136.15 ± 9.11	0.594
Office DBP baseline	78.45 ± 8.4	79.16 ± 8.63	77.79 ± 8.25	0.514
Laboratory measurements				
Haemoglobin (g/L)	138.36 ± 12.72	138.31 ± 13.61	138.41 ± 12.03	0.514
Haematocrit (%)	41.73 ± 3.31	41.46 ± 3.30	41.99 ± 3.35	0.975
Creatinine (umol/L)	68.11 ± 18.38	65.09 ± 16.36	70.94 ± 19.92	0.199
GFR (mL/min/1.73 ²)	101.88 ± 27.06	107.53 ± 25.40	96.56 ± 27.86	0.100

Variable	Total cohort	Dapagliflo- zin	Placebo	P-value
Sodium (mmol/L)	138.92 ± 2.24	138.72 ± 2.16	139.12 ± 2.33	0.474
Potassium (mmol/L)	4.34 ± 0.35	4.23 ± 0.32	4.44 ± 0.35	0.013
Fasting glucose (mmol/L)	8.05 ± 2.96	7.80 ± 3.50	8.05 ± 3.00	0.964
Fasting insulin (uIU/mL) ^{a,e}	11.08	10.56	11.38 ± 11.42	0.521
(n = 48)	(7.43, 18.93)	(6.30, 18.99)	(7.90, 19.320)	
		(n = 22)	(n = 26)	
HOMA-IR ^{a,e}	4.03	4.03 ± 4.26	3.91	0.756
(n = 48)	(2.75, 6.78)	(2.41, 6.67)	(2.96, 7.37)	
		(n = 22)	(n = 26)	
HbA1c (mmol/mol)	60.94 ± 10.61	61.75 ± 11.19	60.18 ± 10.15	0.551
NT-proBNP (pg/mL) ^a	274.42	217.98	365.03	0.218
	(116.12, 568.45)	(82.93, 560.56)	(144.86, 678.12)	
Leptin (pg/mL) ^a	15.65	13.12	17.92	0.124
	(7.48, 30.75)	(5.69, 29.10)	(10.71, 38.94)	
Myeloperoxidase (ng/mL) ^a	117.66	129.14	114.37	0.837
	(64.83, 246.42)	(59.74, 278.11)	(65.03, 216.40)	
NT pro collagen III (ng/mL) ^a	16.60	15.91	17.25	0.878
	(13.42, 20.74)	(13.69, 21.59)	(13.10, 20.74)	
hsCRP (ng/mL) ^a	1696.30	1168.55	2225.01	0.349
	(687.10, 3966.83)	(635.62, 4685.52)	(795.84, 3966.83)	

[Open in new tab](#)

Table 2

Baseline MRI measurements

Variable	Total cohort	Dapagliflozin	Placebo	<i>P</i> -value
Participants randomized	66	32	34	
Absolute LV mass (g)	123.96 ± 22.46	126.47 ± 20.54	121.61 ± 24.20	0.383
LV mass index BSA (g/m ²)	59.95 ± 8.26	60.92 ± 7.76	59.04 ± 8.73	0.360
EF (%)	71.94 ± 5.86	71.31 ± 5.42	72.54 ± 6.27	0.398
EDV (mLs)	124.04 ± 24.07	127.63 ± 22.54	120.66 ± 25.29	0.243
ESV (mLs)	35.34 ± 10.63	37.17 ± 9.92	33.63 ± 11.13	0.178
SV (mLs)	88.42 ± 17.65	90.45 ± 16.36	87.03 ± 18.88	0.435
Left atrial area	23.91 ± 5.25	24.73 ± 5.86	23.13 ± 4.55	0.218
VAT volume (cm ³) ^a	6372.55 ± 2038.19 (<i>n</i> = 65)	6301.79 ± 1988.24 (<i>n</i> = 31)	6437.06 ± 2110.43	0.792
SCAT volume (cm ³) ^a	9135.8 ± 3425.26 (<i>n</i> = 62)	9058.34 ± 3857.04 (<i>n</i> = 31)	9213.27 ± 2994.46 (<i>n</i> = 31)	0.860
VAT/SCAT volume ratio ^a	0.77 ± 0.33 (<i>n</i> = 62)	0.79 ± 0.31 (<i>n</i> = 31)	0.74 ± 0.35 (<i>n</i> = 62)	0.583

[Open in new tab](#)


Primary outcome

Effect of dapagliflozin on LVM

After a mean treatment period of almost 12 months dapagliflozin reduced LVM as measured by MRI in the ITT analysis (change in LVM: dapagliflozin group -3.95 ± 4.85 g vs. placebo group -1.13 ± 4.55 g; *P* = 0.018), leading to an absolute mean difference of

-2.82 g [95% confidence interval (CI): -5.13 to -0.51]. The reduction in LVM was even greater in the per-protocol population (change in LVM: dapagliflozin group -4.36 ± 4.92 g vs. placebo group -1.17 ± 4.43 g; $P = 0.011$), leading to an absolute mean difference of -3.20 g (95% CI: -5.62 to -0.77) (Table 3; Figure 1).


Figure 1



[Open in new tab](#) [Download slide](#)

Column bar charts showing the mean regression of left ventricular mass and left ventricular mass index height^{2.7} following dapagliflozin treatment.

Take home figure



Open in new tabDownload slide
 Proposed mechanisms by which dapagliflozin regressed left ventricular mass.

Table 3
 Changes in parameters measured by cardiac magnetic resonance after 12 months dapagliflozin treatment

Variable	Intention-to-treat analysis				Per-protocol analysis			
	Dapa- gliclo- zin (n = 32)	Pla- cebo (n = 34)	Diffe- rence ^a (95% CI)	P- Va- lue	Dapa- gliclo- zin (n = 29)	Pla- cebo (n = 33)	Diffe- rence ^a (95% CI)	P- Va- lue
Primary endpoint								
Absolute LVM (g)	-3.95 ± 4.85	-1.13 ± 4.55	-2.82 (-5.13 to -0.51)	0.018	-4.36 ± 4.92	-1.17 ± 4.43	-3.2 (-5.62 to -0.77)	0.011
Secondary endpoints								
LVMi BSA (g/m ²)	-0.58 ± 2.29	-0.38 ± 1.79	-0.20 (-1.21 to 0.80)	0.691	-0.64 ± 2.40	-0.39 ± 1.81	-0.25 (-1.32 to 0.82)	0.644

Variable	Intention-to-treat analysis				Per-protocol analysis			
	Dapa- gliflo- zin	Pla- cebo	Diffe- rence	P- Va- lue	Dapa- gliflo- zin	Pla- cebo	Diffe- rence	P- Va- lue
	(n = 32)	(n = 34)	(95% CI)		(n = 29)	(n = 33)	(95% CI)	
LVMH Height (g/m)	-2.33 ± 2.87	-0.71 ± 2.68	-1.62 (-2.99 to -0.26)	0.021	-2.57 ± 2.91	-0.73 ± 2.72	-1.84 (-3.27 to -0.41)	0.013
LVMH Height ^{1.7} (g/m ^{1.7})	-1.61 ± 2.00	-0.51 ± 1.87	-1.09 (-2.05 to -0.15)	0.024	-1.78 ± 2.03	-0.52 ± 1.89	-1.25 (-2.25 to -0.25)	0.015
LVMH Height ^{2.7} (g/m ^{2.7})	-0.95 ± 1.20	-0.32 ± 1.12	-0.63 (-1.21 to -0.06)	0.031	-1.05 ± 1.22	-0.33 ± 1.14	-0.72 (-1.32 to -0.12)	0.020
EF (%)	1.45 ± 4.08	0.66 ± 3.76	0.79 (-1.14 to 2.72)	0.415	1.60 ± 4.26	0.68 ± 3.81	0.92 (-1.13 to 2.97)	0.372
EDV (mLs)	-0.15 ± 11.59	1.44 ± 10.62	-1.59 (-7.06 to 3.87)	0.562	-0.17 ± 12.20	1.48 ± 10.78	-1.65 (-7.49 to 4.18)	0.573
ESV (mLs)	-1.86 ± 4.83	-0.74 ± 4.81	-1.12 (-3.50 to 1.25)	0.348	-2.05 ± 5.04	-0.76 ± 4.89	-1.29 (-3.82 to 1.23)	0.310
SV (mLs)	1.71 ± 11.18	2.18 ± 10.45	-0.47 (-5.79 to 4.85)	0.860	1.88 ± 11.75	2.24 ± 10.60	-0.36 (-6.04 to 5.32)	0.900
Left atrial area (Cm ²) ^b	-0.25 ± 3.38	0.00 ± 3.5	-1.20 (-2.82 to 0.42)	0.143	-0.5 ± 3.75	0.0 ± 3.5	-1.29 (-3.01 to 0.44)	0.088

Open in new tab

Following sensitivity analysis, the reduction in LVM remained greater in the dapagliflozin group compared with placebo: (i) for the ITT arm—estimated marginal means: dapagliflozin group, -4.00 g (95% CI: -5.75 to -2.26) vs. placebo group -1.09 g (95% CI: -2.77 to 0.60) and (ii) per-protocol population—estimated marginal means:

dapagliflozin group, -4.43 g (95% CI: -6.29 to -2.58) vs. placebo group -1.11 g (95% CI: -2.84 to 0.62) and remained statistically significant ($P = 0.025$ for ITT and $P = 0.011$ for per-protocol analysis), suggesting that this finding was robust and not driven by potential relevant baseline characteristics (Supplementary material online, *Table S2*).

Dapagliflozin induced greater LVH regression in those with an above median LVMI at baseline, as might be expected (mean change of -3.88 g (95% CI -7.15 to -0.61, $P = 0.021$) (Supplementary material online, *Table S3*).

Secondary outcomes

Cardiovascular measures

Effect of dapagliflozin on indexed left ventricular mass

Dapagliflozin resulted in significant reductions in LVM indexed to height, height^{1.7} and height^{2.7} in both the ITT and per-protocol populations (Table 3).

This remained the case following sensitivity analysis correcting for the same confounders discussed above (Supplementary material online, *Table S2*).

With the reduction in body weight dapagliflozin did not reduce LMVI to BSA in either the ITT or per protocol population (Table 3). However, when LVM was indexed to baseline BSA dapagliflozin treatment was significant (change in LVMI BSA: dapagliflozin group -2.06 g/m² vs. placebo group -0.65 g/m²; $P = 0.019$) leading to an estimated mean difference of -2.41 g/m² (95% CI: -2.58 to -0.24).

CMR-measured end-diastolic volume, end-systolic volume, left ventricular ejection fraction, stroke volume did not change significantly with dapagliflozin therapy (Table 3).

Effect of dapagliflozin on blood pressure

In both ITT and per-protocol analyses, dapagliflozin significantly reduced 24-h ambulatory SBP and nocturnal systolic BP (Table 4) (Supplementary material online, *Figure S4*). In the ITT analysis, dapagliflozin resulted in a mean difference in 24-h ambulatory SBP of -3.6 mmHg (95% CI: -6.4 to -0.8; $P = 0.012$). Dapagliflozin also resulted in a mean difference in nocturnal systolic BP of -4.4 mmHg (95% CI: to -7.9 to -0.8; $P = 0.017$). These changes remained significant after correction for baseline BP measurements (Supplementary material online, *Table S4*).

Table 4

Changes in blood pressure after 12 months of dapagliflozin treatment

Variable change	Intention-to-treat analysis				Per-protocol analysis			
	Dapa- gliflo- zin	Pla- cebo	Diffe- rence ^a	<i>P</i> - value	Da- pa- gli- flo- zin	Pla- cebo	Diffe- rence ^a	<i>P</i> - value
	(<i>n</i> = 32)	(<i>n</i> = 34)	(95% CI)		(<i>n</i> = 29)	(<i>n</i> = 33)	(95% CI)	
24 h SBP ^b	-2.78 ± 5.94	0.85 ± 5.40 (<i>n</i> = 33)	-3.63 (-6.44 to -0.82)	0.012	-3.07 ± 6.18	0.88 ± 5.48 (<i>n</i> = 32)	-3.94 (-6.93 to -0.96)	0.011
24 h DBP ^b	-0.94 ± 3.98	0.06 ± 4.87 (<i>n</i> = 33)	-0.1 (-3.2 to 1.21)	0.370	-1.03 ± 4.18	0.06 ± 4.94 (<i>n</i> = 32)	-1.1 (-3.46 to 1.260)	0.356
Heart rate ^{b-d}	-2.00 ± 5.75	1.00 ± 8.50 (<i>n</i> = 33)	-2.1 (-5.64 to 1.43)	0.184	-2.0 ± 7.5	1.0 ± 8.80 (<i>n</i> = 32)	-2.27 (-6.05 to 1.51)	0.183
Day- time SBP ^b	-2.47 ± 6.56	0.55 ± 6.45 (<i>n</i> = 33)	-3.01 (-6.24 to 0.21)	0.066	-2.72 ± 6.85	0.56 ± 6.55 (<i>n</i> = 32)	-3.29 (-6.72 to 0.15)	0.060
Day- time DBP ^b	-1.03 ± 5.18	0.24 ± 5.80 (<i>n</i> = 33)	-1.27 (-4.00 to 1.46)	0.355	-1.14 ± 5.44	0.25 ± 5.90 (<i>n</i> = 32)	-1.39 (-4.30 to 1.53)	0.345
Noctur- nal SBP ^e	-3.47 ± 7.54	0.91 ± 6.70 (<i>n</i> = 32)	-4.38 (-7.94 to -0.81)	0.017	-3.83 ± 7.84	0.94 ± 6.81 (<i>n</i> = 31)	-4.76 (-8.55 to -0.98)	0.015
Noctur- nal DBP ^e	-2.25 ± 5.90	0.16 ± 4.14 (<i>n</i> = 32)	-2.41 (-4.95 to 0.14)	0.063	-2.48 ± 6.16	0.16 ± 4.20 (<i>n</i> = 31)	-2.64 (-5.35 to 0.06)	0.059
Office SBP	-5.28 ± 8.63	-1.79 ± 7.26	-3.49 (-7.40 to 0.43)	0.080	-5.83 ± 8.89	-1.85 ± 7.37	-3.98 (-8.11 to 0.15)	0.059
Office DBP	-2.97 ± 5.62	-2.24 ± 7.48	-0.73 (-4.00 to 2.54)	0.656	-3.27 ± 5.82	-2.30 ± 7.58	-0.97 (-4.39 to 2.44)	0.577

Open in new tab

There was an observed moderate correlation between change in LVM and change in ambulatory 24 SBP and nocturnal SBP with $r = 0.415$, $n = 61$, $P = 0.001$, and $r = 0.321$, $n = 60$, $P = 0.012$, respectively.

There were only four changes in total to the antihypertensive with two dose reductions in the dapagliflozin arm and one dose reduction and one dose increase in the placebo arm.

Metabolic outcomes

Effect of dapagliflozin on obesity parameters

The ITT analysis consisted of 65 participants where complete visceral adipose tissue (VAT) volumes were available for analysis (31 and 34 in dapagliflozin arm and placebo arm, respectively) and 62 where complete subcutaneous adipose tissue (SCAT) volumes were available for analysis (31 in each arm). One participant was unable to complete the abdominal MRI at the final visit due to claustrophobia. Therefore, in the per-protocol population there were 60 participants where complete VAT volumes were available for analysis (28 and 32 in dapagliflozin and placebo arm, respectively), and 57 participants where complete SCAT volumes were available for analysis (28 and 29 in dapagliflozin and placebo arm, respectively).

In both the ITT and the per-protocol population dapagliflozin treatment significantly reduced VAT and SCAT (Table 5) (Supplementary material online, *Figure S5*).

Table 5

Changes in obesity parameters after 12 months dapagliflozin treatment

Variable change	Intention-to-treat analysis				Per-protocol analysis			
	Dapa-gliflo-zin	Pla-cebo	Diffe-rence ^a	P-value	Dapa-gliflo-zin	Pla-cebo	Diffe-rence ^a	P-value
	(n = 32)	(n = 34)	(95% CI)		(n = 29)	(n = 33)	(95% CI)	
Weight (kg)	-4.27 ± 2.50	-0.50 ± 2.19	-3.77 (-4.92 to -2.61)	<0.001	-4.56 ± 2.41	-0.52 ± 2.22	-4.03 (-5.21 to -2.86)	<0.001

Variable change	Intention-to-treat analysis				Per-protocol analysis			
	Dapa- gliflo- zin	Pla- cebo	Diffe- rence	P- value	Dapa- gliflo- zin	Pla- cebo	Diffe- rence	P- value
	(n = 32)	(n = 34)	(95% CI)		(n = 29)	(n = 33)	(95% CI)	
BMI (kg/m ²) ^b	-1.53 ± 0.93	-0.17 ± 0.74	-1.35 (-1.77 to -0.94)	<0.001	-1.63 ± 0.91	-0.18 ± 0.75	-1.45 (-1.87 to -1.03)	<0.001
VAT vo- lume (cm ³) ^c	-565.17 ± 691.27	114.22 ± 593.69	-679.4 (-998.00 to -360.80)	<0.001	-625.73 ± 701.18	121.36 ± 611.81	-747.09 (-1086.34 to -407.84)	<0.001
SCAT vo- lume (cm ³) ^c	-720.84 ± 687.83	-111.08 ± 643.42	-609.76 (-948.13 to -271.28)	0.001	-798.07 ± 679.52	-118.74 ± 665.30	-679.33 (-1036.47 to -322.19)	<0.001
VAT/SCAT volume ratio ^c	(n = 31) -0.01 ± 0.06	0.02 ± 0.06 (n = 31)	-0.03 (-0.06 to 0.00)	0.023	(n = 28) -0.01 ± 0.06	0.021 ± 0.057 (n = 29)	-0.04 (-0.07 to -0.01)	0.023

Open in new tab

This also meant dapagliflozin significantly reduced the VAT/SCAT ratio in both the ITT ($P = 0.023$) and the per-protocol ($P = 0.023$) populations. There was an observed strong correlation between change in LVM and change in VAT, $r = 0.592$, $n = 60$, $P < 0.001$, and moderate correlation between change in LVM and change in SCAT $r = 0.360$, $n = 57$, $P = 0.006$.

Compared with placebo in both analyses dapagliflozin treatment resulted in significant reduction in weight. Mixed model analysis of the per-protocol population showed the weight loss effect to be most significant with the first 4–6 months of

treatment (Supplementary material online, *Figure S6*).

Effect of dapagliflozin on blood parameters

In this study, 11.9 months dapagliflozin therapy increased both haemoglobin and haematocrit from baseline. Dapagliflozin reduced fasting glucose, glycated haemoglobin and improved HOMA-IR, and reduced hsCRP compared with placebo (Table 6).

Table 6
Changes in safety and research blood parameters after 12 months dapagliflozin treatment

Variable	Intention-to-treat analysis			
	Dapagliflozin (n = 32)	Placebo (n = 34)	Difference ^a (95%CI)	P-value
Haemoglobin (g/L)	7.00 ± 11.75	-2.00 ± 5.00	9.51 (5.85 to 13.18)	<0.001
Haematocrit (%)	2.60 ± 0.02	0.30 ± 0.02	2.90 (1.84 to 3.96)	<0.001
Creatinine (umol/L)	1.34 ± 5.89	-0.91 ± 5.83	2.26 (-0.63 to 5.14)	0.123
cGFR (mL/min/1.732)	-1.16 ± 10.48	1.59 ± 7.19	-2.74 (-7.14 to 1.65)	0.217
Sodium (mmol/L)	-0.75 ± 2.05	0.38 ± 1.83	-1.13 (-2.09 to 0.18)	0.121
Potassium (mmol/L)	-0.03 ± 0.26	-0.04 ± 0.30	-0.01 (-0.12 to 0.15)	0.852
Fasting glucose (mmol/L)	-1.06 ± 2.08	0.62 ± 2.11	-1.68 (-2.71 to -0.65)	0.002
HbA1c (mmol/mol)	-6.28 ± 8.25	-0.79 ± 10.89	-5.49 (-10.26 to -0.71)	0.025
NT-proBNP (pg/mL) ^b	7.14 ± 138.69	40.19 ± 219.47	-103.68 (-326.90 to 119.54)	0.551
Leptin (pg/mL) ^b	-447.55 ± 5299.58	477.6 ± 6314.88	-2931.7 (-6901.46 to 1038.07)	0.256

Intention-to-treat analysis

Variable	Dapagliflozin	Placebo	Difference	P-value
	(n = 32)	(n = 34)	(95%CI)	
Myeloperoxidase (ng/mL) ^b	0.00 ± 107.04	-36.49 ± 85.63	23.02 (-31.05 to 77.08)	0.172
NT-pro collagen III (ng/mL)	-0.44 ± 5.06	-0.1 ± 4.24	-0.46 (-2.20 to 1.29)	0.653
hsCRP (ng/L) ^b	-163.73 ± 1040.76	66.73 ± 1258.37	-1296.04 (-2650.59 to -31.50)	0.049
Fasting insulin (uU/mL) (n = 48) ^{b,c}	-2.34 ± 5.59 (n = 22)	-0.58 ± 7.14 (n = 26)	-3.61 (-6.97 to -0.26)	0.098
HOMA-IR (n = 48) ^{b,c}	-2.1 ± 2.37 (n = 22)	0.46 ± 3.23 (n = 26)	-2.56 (-4.47 to -0.65)	0.017

[Open in new tab](#)

Tolerability and safety of dapagliflozin

In total, there were 169 adverse events, 86 events in the dapagliflozin arm and 83 in the placebo arm although most of these were transient and mild to moderate in severity. There were no reported cases of diabetic ketoacidosis. There were five serious adverse events recorded during the trial (two in the dapagliflozin arm and three in the placebo arm). The incidence of common side effects reported with SGLT2i is illustrated in Supplementary material online, *Table S5*.

Discussion

The main finding of our study is that following 1-year of dapagliflozin (10 mg) there were significant reductions in CMR-measured LVM in normotensive T2D participants who had LVH at baseline. Dapagliflozin was also shown to significantly reduce measures of body weight and VAT, 24-h ambulatory and nocturnal SBP and insulin resistance that maybe implicated in the pathophysiology of LVH in T2D.

To the best of our knowledge, this is the first randomized controlled trial investigating the effect of dapagliflozin on LVH in patients with T2D. We found that dapagliflozin reduced LVM by 3.95 g when compared to a reduction of 1.13 g in the placebo group. The small reduction in LVM observed in the placebo group in our study is not unexpected and is often reported in clinical trials. This is likely because our clinical participants were closely monitored at all trial visits to ensure adequate BP and glycaemic control. This close monitoring of participants likely accounted for the modest weight loss and reduction in SCAT reduction, HbA1c and insulin resistance observed in the placebo group. Consistent with the current study, the EMPA-HEART reported that empagliflozin promoted reverse LV remodelling in patients with diabetes, empagliflozin resulted in a significant reduction in LVMI (-2.6 vs. -0.01 g/m², $P = 0.01$).²⁸ It is noteworthy that a recent subgroup analysis of the EMPA-REG OUTCOME trial, reported that the reduction of CVD, MI, and stroke was greater in patients with LVH than in those without LVH, a finding supported by the current study where we found that LVH regression was greater in those with higher baseline LVM.²⁹ This suggests that SGLT inhibition may have a greater effect in this higher risk subgroup. Left ventricular hypertrophy regression reduces the incidences of all major CV events; including sudden deaths, heart failure hospitalizations, new onset atrial fibrillation, and strokes independent of BP changes; therefore, our data would suggest that SGLT2i therapy may be warranted for T2D with LVH irrespective of the level of glycaemic control.³⁰⁻⁴⁰

There are a number of plausible mechanisms that may explain dapagliflozin induced LVM regression some of which have been explored in this study (Take home figure).⁴¹ Firstly, dapagliflozin could mediate LVH regression through its effect to reduce SBP. Furthermore, there was also a statistically significant correlation between ambulatory SBP reduction and LVM regression that might support this plausible mechanism. Trials have consistently shown that SGLT2i lead to a reduction in SBP in the range of 3–5 mmHg in patients with T2D.⁴² The magnitude of BP reduction was similar to that observed in our study. We also observed that there was a significant drop in nocturnal SBP rather than daytime SBP. The loss of nocturnal decline in BP has been established as an important marker for CV risk, independent of overall BP during a 24-h period.⁴³

A second mechanism is reduction in preload secondary to natriuresis and osmotic diuresis which would improve ventricular loading conditions reducing LV wall stress and thus contribute to regression of LVM.¹² Indeed, mediation analysis from the EMPA-REG OUTCOME trial has suggested that volume contraction is likely a key component of the CV benefit noted in the trial. It has been suggested that ~ 50% of the CV benefit seen in the trial could be attributed to empagliflozin induced haemoconcentration.⁴⁴ We did not observe any significant change in NT-proBNP but

we did observe a significant increase in haematocrit possibly secondary to decreased plasma volume with resultant haemoconcentration. It is worth noting that the lack of a drop in NT-proBNP may be result of the decrease in body weight.⁴⁵

Obesity is a separate albeit related factor mediating LVH.^{15,46} A third plausible mechanism for LVH regression seen in this study may be dapagliflozin induced reduction in body weight. Sodium-glucose cotransporter 2 inhibitors have consistently been shown to lead to weight reduction of 2–3 kg.⁴² The weight loss, however, does appear to plateau after 3–6 months.⁴⁷ In this study, dapagliflozin significantly reduced weight on average by 4 kg and the weight loss was most significant in the first 4–6 months of therapy. The weight loss associated with selective SGLT2 inhibition is likely due to the glucose excretion with associated caloric loss.⁴⁸

In our study, dapagliflozin also resulted in a mean reduction in VAT and SCAT of around 700 and 600 cm³, respectively, compared with placebo. Visceral fat is well recognized to be associated with an increased risk of T2D mellitus, CV complications and overall mortality and associated insulin resistance, inflammation, and oxidative stress.^{49–52} Whilst we did not observe a significant change in oxidative stress with no change in myeloperoxidase, we did see a significant reduction in hsCRP which has been seen before in studies with dapagliflozin.^{53,54} Chronic low-grade inflammation is recognized a key feature in T2D and its complications including diabetic cardiomyopathy. The observed strong correlation between VAT reduction and LVM regression suggests that a reduction in VAT-mediated inflammation may lead to improved CV remodelling.

Finally, SGLT2i-induced glycosuria has been shown to improve β cell function and insulin sensitivity and this improvement in insulin sensitivity could have mediated the LVM regression.^{55,56} Insulin resistance is thought to contribute to changes in cardiac tissue seen in LVH.⁵⁷ In our study, dapagliflozin treatment resulted in a significant reduction in fasting glucose, fasting insulin, and glycated haemoglobin. Due to time and financial constraints, we did not perform a hyperinsulinaemic euglycaemic clamp, the 'gold standard' for the measurement of insulin sensitivity but we did see that dapagliflozin resulted in a significant reduction in HOMA-IR an index for insulin resistance.

Limitation of the study

This was a single-centre study with relatively small number of people. However, this trial is the first prospective, adequately powered RCT conducted to date, investigating the efficacy of dapagliflozin to regress LVH. Secondly, it is noteworthy that the cardiac MRI analysis was performed by only a single operator that did not allow us to assess inter-observer variability and there is the possible effect of learning on the reported intra-observer variability. Thirdly, the study was statistically powered only for a single

outcome and not statistically powered to detect changes in other secondary endpoints. Therefore, inferential between group comparisons for these secondary endpoints is likely to be exploratory rather than definitive. Although there were no statistically significant differences between the two groups, because of the relatively small sample size, we cannot exclude the possibility that some subtle baseline and demographic differences between two groups might have collectively contributed to our results.

Conclusion and future directions

In conclusion, this study has shown, for the first time in a randomized controlled trial that dapagliflozin treatment significantly reduces LVM compared with placebo in people with T2D, LVH, and controlled BP. This is consistent with the results seen with empagliflozin in EMPA-HEART and these independent reports provide excellent validation for both studies.

Dapagliflozin improved SBP, increased haematocrit and in addition we have shown that dapagliflozin reduced measures of obesity such as body weight, SCAT, and VAT and reduced insulin resistance and markers of inflammation.

The regression of LVM suggests dapagliflozin can initiate reverse remodelling and changes in left ventricular structure that may partly contribute to the reported cardio-protective effects of dapagliflozin.

Acknowledgements

The authors would like to thank SDRN and SPCRN for helping in recruiting participants for this study. We would also like to acknowledge Tayside Clinical Trials Unit (TCTU), University of Dundee, for their contribution to this study and Mike Lonergan for statistical support.

Funding

Externally Sponsored Research grant from Astra Zeneca (grant number ESR-14-10168).

Conflict of interest: R.J.M. grant funding from Helmsley Trust, Diabetes UK, Juvenile Diabetes Research Foundation, Eu IMI, MRC UK and Astra Zeneca and honoraria from Eli Lilly. A.D.S. declares consultancy fees from AstraZeneca. C.C.L. declares receiving consultancy fees and/or research grants from Amgen, AstraZeneca, MSD, Novartis, and Servier. A.J.M.B., S.G., and G.H. have no conflict of interest to declare.

References

1

Haffner

SM

,
Lehto

S

,
Ronnemaa

T

,
Pyorala

K

,
Laakso

M.

Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction

.
N Engl J Med

1998

;
339

:
229

-2
34

.

2

Di Angelantonio

E

,
Kaptoge

S

,
Wormser

D

,
Willeit

P

,
Butterworth

AS

,
Bansal

N

,
O'Keeffe

LM

,
Gao

P

,
Wood

AM

,

Burgess

S

,
Freitag

DF

,
Pennells

L

,
Peters

SA

,
Hart

CL

,
Haheim

LL

,
Gillum

RF

,
Nordestgaard

BG

,
Psaty

BM

,
Yeap

BB

,
Knuiman

MW

,
Nietert

PJ

,
Kauhanen

J

,
Salonen

JT

,
Kuller

LH

,
Simons

LA

,
van der Schouw

YT

,
Barrett-Connor

E

,
Selmer

R

,
Crespo

CJ

,
Rodriguez

B

,
Verschuren

WM

,
Salomaa

V

,
Svardsudd

K

,
van der Harst

P

,
Bjorkelund

C

,
Wilhelmsen

L

,
Wallace

RB

,

Brenner

H

,
Amouyel

P

,
Barr

EL

,
Iso

H

,
Onat

A

,
Trevisan

M

,
D'Agostino

RB

Sr ,
Cooper

C

,
Kavousi

M

,
Welin

L

,
Roussel

R

,
Hu

FB

,
Sato

S

,
Davidson

KW

,
Howard

BV

,
Leening

MJ

,
Rosengren

A

,
Dorr

M

,
Deeg

DJ

,
Kiechl

S

,
Stehouwer

CD

,
Nissinen

A

,
Giampaoli

S

,
Donfrancesco

C

,
Kromhout

D

,
Price

JF

,
Peters

A

,
Meade

TW

,

Casiglia

E

,
Lawlor

DA

,
Gallacher

J

,
Nagel

D

,
Franco

OH

,
Assmann

G

,
Dagenais

GR

,
Jukema

JW

,
Sundstrom

J

,
Woodward

M

,
Brunner

EJ

,
Khaw

KT

,
Wareham

NJ

,
Whitsel

EA

,
Njolstad

I

,
Hedblad

B

,
Wassertheil-Smoller

S

,
Engstrom

G

,
Rosamond

WD

,
Selvin

E

,
Sattar

N

,
Thompson

SG

,
Danesh

J.

Association of cardiometabolic multimorbidity with mortality

.
JAMA

2015

;
314

:
52

–
60

.
3

Kannel

WB

,
Hjortland

M

,
Castelli

WP.

Role of diabetes in congestive heart failure: the Framingham study

.
Am J Cardiol

1974

;
34

:
29

—
34

.
4

Stratton

IM

,
Adler

AI

,
Neil

HA

,
Matthews

DR

,

Manley

SE

**,
Cull**

CA

**,
Hadden**

D

**,
Turner**

RC

**,
Holman**

RR.

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

**.
BMJ**

2000

**;
321**

**;
405**

**-4
12**

**.
Google Scholar**

**Crossref
PubMed**

5

Buse

JB

,
Bigger

JT

,
Byington

RP

,
Cooper

LS

,
Cushman

WC

,
Friedewald

WT

,
Genuth

S

,
Gerstein

HC

,
Ginsberg

HN

,
Goff

DC

Jr ,
Grimm

RH

Jr ,
Margolis

KL

,
Probstfield

JL,

,
Simons-Morton

DG

,
Sullivan

MD.

Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods

.
Am J Cardiol

2007

;
99

:
21i

—
33i

.
Google Scholar

Crossref
PubMed

6

Patel

A

,
MacMahon

S

,
Chalmers

J

,
Neal

B

,
Billot

L

,
Woodward

M

,
Marre

M

,
Cooper

M

,
Glasziou

P

,
Grobbee

D

,
Hamet

P

,
Harrap

S

,
Heller

S

,
Liu

L

,
Mancia

G

,
Mogensen

CE

,
Pan

C

,

Poulter

N

**,
Rodgers**

A

**,
Williams**

B

**,
Bompoint**

S

**,
de Galan**

BE

**,
Joshi**

R

**,
Travert**

F.

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes

**.
N Engl J Med**

2008

**;
358**

:

2560

-25

72

.

Google Scholar

Crossref

PubMed

7

Duckworth

W

,

Abraira

C

,

Moritz

T

,

Reda

D

,

Emanuele

N

,

Reaven

PD

,

Zieve

FJ

,
Marks

J

,
Davis

SN

,
Hayward

R

,
Warren

SR

,
Goldman

S

,
McCarren

M

,
Vitek

ME

,
Henderson

WG

,
Huang

GD.

Glucose control and vascular complications in veterans with type 2 diabetes

.
N Engl J Med

2009

;
360

:
129

-1
39

.
Google Scholar

Crossref
PubMed

8

Zinman

B

,
Wanner

C

,
Lachin

JM

,
Fitchett

D

,
Bluhmki

E

,
Hantel

S

,
Mattheus

M

,
Devins

T

,
Johansen

OE

,
Woerle

HJ

,
Broedl

UC

,
Inzucchi

SE.

Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes

.
N Engl J Med

2015

;
373

:

2117

-21

28

.

Google Scholar

Crossref

PubMed

9

Wiviott

SD

,

Raz

I

,

Bonaca

MP

,

Mosenzon

O

,

Kato

ET

,

Cahn

A

,

Silverman

MG

,
Zelniker

TA

,
Kuder

JF

,
Murphy

SA

,
Bhatt

DL

,
Leiter

LA,

,
McGuire

DK

,
Wilding

JPH

,
Ruff

CT

,
Gause-Nilsson

IAM

,

Fredriksson

M

,
Johansson

PA

,
Langkilde

AM,

,
Sabatine

MS.

Dapagliflozin and cardiovascular outcomes in type 2 diabetes

.
N Engl J Med

2019

;
380

;
347

-3
57

.
Google Scholar

Crossref
PubMed

10

Neal

B

,
Perkovic

V

,
Mahaffey

KW

,
de Zeeuw

D

,
Fulcher

G

,
Erondu

N

,
Shaw

W

,
Law

G

,
Desai

M

,
Matthews

DR.

Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017; 377

: 644

– 657

. 11

McMurray

JJV

, Solomon SD, Inzucchi SE, Kober L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Anand IS, Bělohávek J, Böhm M, Chiang CE, Chopra VK, de Boer RA, Desai AS, Diez M, Drozd J, Dukát A, Ge J, Howlett JG, Katova T, Kitakaze M, Ljungman CEA, Merkely B, Nicolau JC, O'Meara E, Petrie MC, Vinh PN, Schou M, Tereshchenko S, Verma S, Held C, DeMets DL, Docherty KF, Jhund PS, Bengtsson O, Sjöstrand M, Langkilde AM; DAPA-HF Trial Committees and Investigators. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 2019; 381

: 1995

– 2008

. 12

Verma

S

, McMurray

JJV.

SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review

.
Diabetologia

2018

;
61

;
2108

-21
17

.
Google Scholar

Crossref
PubMed

13

De Jong

KA

,
Czeczor

JK

,
Sithara

S

,
McEwen

K

,
Lopaschuk

GD

'
Appelbe

A

'
Cukier

K

'
Kotowicz

M

'
McGee

SL.

Obesity and type 2 diabetes have additive effects on left ventricular remodelling in normotensive patients-a cross sectional study

·
Cardiovasc Diabetol

2017

;
16

:
21

·
Google Scholar

Crossref
PubMed

14

Dawson

A

,
Morris

AD

,
Struthers

AD.

The epidemiology of left ventricular hypertrophy in type 2 diabetes mellitus

.
Diabetologia

2005

;
48

;
1971

-197
9

.
Google Scholar

Crossref
PubMed

15

Rutter

MK

,
Parise

H

,
Benjamin

EJ

,
Levy

D

,
Larson

MG

,
Meigs

JB

,
Nesto

RW

,
Wilson

PW

,
Vasan

RS.

Impact of glucose intolerance and insulin resistance on cardiac structure and function: sex-related differences in the Framingham Heart Study

.
Circulation

2003

;
107

:
448

-4

54

.

Google Scholar

Crossref

PubMed

16

Chaturvedi

N

,

McKeigue

PM

,

Marmot

MG

,

Nihoyannopoulos

P.

A comparison of left ventricular abnormalities associated with glucose intolerance in African Caribbeans and Europeans in the UK

.

Heart

2001

;

85

:

643

-64

8

.
Google Scholar

Crossref
PubMed

17

Arnett

DK

,
Hong

Y

,
Bella

JN

,
Oberman

A

,
Kitzman

DW

,
Hopkins

PN

,
Rao

DC

,
Devereux

RB.

Sibling correlation of left ventricular mass and geometry in hypertensive African Americans and whites: the HyperGEN study. Hypertension Genetic Epidemiology Network

.
Am J Hypertens

2001

;
14

;
1226

-12
30

.
Google Scholar

Crossref
PubMed

18

Lauer

MS

,
Anderson

KM

,
Kannel

WB

,
Levy

D.

The impact of obesity on left ventricular mass and geometry. The Framingham Heart Study

.
JAMA

1991

;
266

:
231

-23
6

.
Google Scholar

Crossref
PubMed

19

Peterson

LR

,
Waggoner

AD

,
Schechtman

KB

,
Meyer

T

,
Gropler

RJ

,
Barzilai

B

,
Davila-Roman

VG.

**Alterations in left ventricular structure and function in young healthy obese women:
assessment by echocardiography and tissue Doppler imaging**

.
J Am Coll Cardiol

2004

;
43

:
1399

-1
404

.
Google Scholar

Crossref
PubMed

20

Wong

CY

,
O'Moore-Sullivan

T

,
Leano

R

,
Byrne

N

,
Beller

E

,
Marwick

TH.

Alterations of left ventricular myocardial characteristics associated with obesity

.
Circulation

2004

;
110

:
3081

-308
7

.
Google Scholar

Crossref
PubMed

21

Cooper

RS

,
Simmons

BE

,
Castaner

A

,
Santhanam

V

,
Ghali

J

,
Mar

M.

Left ventricular hypertrophy is associated with worse survival independent of ventricular function and number of coronary arteries severely narrowed

.
Am J Cardiol

1990

;
65

:
441

-44

5

.
Google Scholar

**Crossref
PubMed**

22

Liao

Y

**,
Cooper**

RS

**,
McGee**

DL

**,
Mensah**

GA

**,
Ghali**

JK.

**The relative effects of left ventricular hypertrophy, coronary artery disease, and
ventricular dysfunction on survival among black adults**

**.
JAMA**

1995

**;
273**

**:
1592**

**-159
7**

.
Google Scholar

Crossref
PubMed

23

Brown

AJM

,
Lang

C

,
McCrimmon

R

,
Struthers

A.

Does dapagliflozin regress left ventricular hypertrophy in patients with type 2 diabetes? A prospective, double-blind, randomised, placebo-controlled study

.
BMC Cardiovasc Disord

2017

;
17

;
229

.
Google Scholar

Crossref
PubMed

24

Lang

RM

,
Badano

LP

,
Mor-Avi

V

,
Afilalo

J

,
Armstrong

A

,
Ernande

L

,
Flachskampf

FA

,
Foster

E

,
Goldstein

SA

,
Kuznetsova

T

,
Lancellotti

P

,
Muraru

D

,
Picard

MH

,
Rietzschel

ER

,
Rudski

L

,
Spencer

KT

,
Tsang

W

,
Voigt

JU.

**Recommendations for cardiac chamber quantification by echocardiography in adults:
an update from the American Society of Echocardiography and the European
Association of Cardiovascular Imaging**

.
J Am Soc Echocardiogr

2015

;
28

:
1

–
39.e14

.
Google Scholar

**Crossref
PubMed**

25

Rekhranj

S

,
Gandy

SJ

,
Szwejkowski

BR

,
Nadir

MA

,

Noman

A

**,
Houston**

JG

**,
Lang**

CC

**,
George**

J

**,
Struthers**

AD.

High-dose allopurinol reduces left ventricular mass in patients with ischemic heart disease

**.
J Am Coll Cardiol**

2013

**;
61**

**;
926**

**-9
32**

**.
Google Scholar**

**Crossref
PubMed**

26

Szwejkowski

BR

,
Gandy

SJ

,
Rekhraj

S

,
Houston

JG

,
Lang

CC

,
Morris

AD

,
George

J

,
Struthers

AD.

Allopurinol reduces left ventricular mass in patients with type 2 diabetes and left ventricular hypertrophy

.

J Am Coll Cardiol

2013

;
62

;
2284

-22
93

.
Google Scholar

Crossref
PubMed

27

Devereux

RB

,
Dahlof

B

,
Gerdtz

E

,
Boman

K

,
Nieminen

MS

,

Papademetriou

V

**,
Rokkedal**

J

**,
Harris**

KE

**,
Edelman**

JM

**,
Wachtell**

K.

Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial

**.
Circulation**

2004

**;
110**

**:
1456**

**-14
62**

**.
Google Scholar**

Crossref

PubMed

28

Verma

S

**,
Mazer**

CD

**,
Yan**

AT

**,
Mason**

T

**,
Garg**

V

**,
Teoh**

H

**,
Zuo**

F

**,
Quan**

A

**,
Farkouh**

ME

,
Fitchett

DH

,
Goodman

SG

,
Goldenberg

RM

,
Al-Omran

M

,
Gilbert

RE

,
Bhatt

DL

,
Leiter

LA

,
Juni

P

,
Zinman

B

,
Connelly

KA.

Effect of empagliflozin on left ventricular mass in patients with type 2 diabetes mellitus and coronary artery disease: the EMPA-HEART cardioliNK-6 randomized clinical trial

.
Circulation

2019

;
140

:
1693

-1
702

.
Google Scholar

Crossref
PubMed

29

Verma

S

,
Mazer

CD

,
Bhatt

DL

,

Raj

SR

,
Yan

AT

,
Verma

A

,
Ferrannini

E

,
Simons

G

,
Lee

J

,
Zinman

B

,
George

JT

,
Fitchett

D.

Empagliflozin and cardiovascular outcomes in patients with type 2 diabetes and left ventricular hypertrophy: a subanalysis of the EMPA-REG OUTCOME trial

.
Diabetes Care

2019

;
42

:
e42

–
e44

.
Google Scholar

Crossref
PubMed

30

Verdecchia

P

,
Schillaci

G

,
Borgioni

C

,
Ciucci

A

,
Gattobigio

R

,
Zampi

I

,
Reboldi

G

,
Porcellati

C.

Prognostic significance of serial changes in left ventricular mass in essential hypertension

.
Circulation

1998

;
97

;
48

—
54

.
Google Scholar

Crossref
PubMed

31

Verdecchia

P

,
Angeli

F

,
Borgioni

C

,
Gattobigio

R

,
de Simone

G

,
Devereux

RB

,
Porcellati

C.

**Changes in cardiovascular risk by reduction of left ventricular mass in hypertension:
a meta-analysis**

.
Am J Hypertens

2003

;
16

(
11 Pt 1

):
895

-89

9

.
Google Scholar

Crossref
PubMed

32

Verdecchia

P

,
Angeli

F

,
Gattobigio

R

,
Sardone

M

,
Pede

S

,
Reboldi

GP.

Regression of left ventricular hypertrophy and prevention of stroke in hypertensive subjects

.
Am J Hypertens

2006

;

19

:
493

-49
9

.
Google Scholar

Crossref
PubMed

33

Okin

PM

,
Wachtell

K

,
Devereux

RB

,
Harris

KE

,
Jern

S

,
Kjeldsen

SE

,

Julius

S

**,
Lindholm**

LH

**,
Nieminen**

MS

**,
Edelman**

JM

**,
Hille**

DA

**,
Dahlof**

B.

Regression of electrocardiographic left ventricular hypertrophy and decreased incidence of new-onset atrial fibrillation in patients with hypertension

**.
JAMA**

2006

**;
296**

**;
1242**

**-124
8**

.
Google Scholar

Crossref
PubMed

34

Okin

PM

,
Devereux

RB

,
Harris

KE

,
Jern

S

,
Kjeldsen

SE

,
Julius

S

,
Edelman

JM

,
Dahlof

B.

Regression of electrocardiographic left ventricular hypertrophy is associated with less hospitalization for heart failure in hypertensive patients

.
Ann Intern Med

2007

;
147

;
311

-31
9

.
Google Scholar

Crossref
PubMed

35

Wachtell

K

,
Okin

PM

,
Olsen

MH

,
Dahlof

B

,
Devereux

RB

,
Ibsen

H

,
Kjeldsen

SE

,
Lindholm

LH

,
Nieminen

MS

,
Thygesen

K.

**Regression of electrocardiographic left ventricular hypertrophy during
antihypertensive therapy and reduction in sudden cardiac death: the LIFE Study**

.
Circulation

2007

;
116

:
700

-70

5

.
Google Scholar

**Crossref
PubMed**

36

Koren

MJ

**,
Ulin**

RJ

**,
Koren**

AT

**,
Laragh**

JH

**,
Devereux**

RB.

Left ventricular mass change during treatment and outcome in patients with essential hypertension

**.
Am J Hypertens**

2002

**;
15**

**;
1021**

**-102
8**

.
Google Scholar

Crossref
PubMed

37

Okin

PM

,
Devereux

RB

,
Jern

S

,
Kjeldsen

SE

,
Julius

S

,
Nieminen

MS

,
Snapinn

S

,
Harris

KE

,
Aurup

P

,
Edelman

JM

,
Wedel

H

,
Lindholm

LH

,
Dahlof

B.

Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events

.
JAMA

2004

;
292

:
2343

-234

9

.
Google Scholar

Crossref

PubMed

38

Ruilope

LM

**,
Schmieder**

RE.

Left ventricular hypertrophy and clinical outcomes in hypertensive patients

**.
Am J Hypertens**

2008

**;
21**

**:
500**

**-50
8**

**.
Google Scholar**

**Crossref
PubMed**

39

Dahlof

B

**,
Devereux**

RB

,
Kjeldsen

SE

,
Julius

S

,
Beevers

G

,
de Faire

U

,
Fyhrquist

F

,
Ibsen

H

,
Kristiansson

K

,
Lederballe-Pedersen

O

,
Lindholm

LH

,

Nieminen

MS

,
Omvik

P

,
Oparil

S

,
Wedel

H

,
Group

LS.

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

.
Lancet

2002

;
359

;
995

–
1003

.
Google Scholar

Crossref
PubMed

40

Brown

DW

,
Giles

WH

,
Croft

JB.

Left ventricular hypertrophy as a predictor of coronary heart disease mortality and the effect of hypertension

.
Am Heart J

2000

;
140

:
848

-8
56

.
Google Scholar

Crossref
PubMed

41

Filippatos

TD

,
Liontos

A

,
Papakitsou

I

,
Elisaf

MS.

SGLT2 inhibitors and cardioprotection: a matter of debate and multiple hypotheses

.
Postgrad Med

2019

;
131

:
82

-8
8

.
Google Scholar

Crossref
PubMed

42

Vasilakou

D

,
Karagiannis

T

,
Athanasiadou

E

,
Mainou

M

,
Liakos

A

,
Bekiari

E

,
Sarigianni

M

,
Matthews

DR

,
Tsapas

A.

**Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review
and meta-analysis**

.
Ann Intern Med

2013

;

159

:

262

-2

74

.

Google Scholar

Crossref

PubMed

43

Ohkubo

T

,

Hozawa

A

,

Yamaguchi

J

,

Kikuya

M

,

Ohmori

K

,

Michimata

M

,

Matsubara

M

,
Hashimoto

J

,
Hoshi

H

,
Araki

T

,
Tsuji

I

,
Satoh

H

,
Hisamichi

S

,
Imai

Y.

Prognostic significance of the nocturnal decline in blood pressure in individuals with and without high 24-h blood pressure: the Ohasama study

.
J Hypertens

2002

;
20

:
2183

-218
9

.
44

Inzucchi

SE

,
Zinman

B

,
Fitchett

D

,
Wanner

C

,
Ferrannini

E

,
Schumacher

M

,
Schmoor

C

,
Ohneberg

K

,
Johansen

OE

,
George

JT

,
Hantel

S

,
Bluhmki

E

,
Lachin

JM.

How does empagliflozin reduce cardiovascular mortality? Insights from a mediation analysis of the EMPA-REG OUTCOME trial

.
Diabetes Care

2018

;
41

;
356

-3
63

.
45

Kistorp

C

,
Bliddal

H

,
Goetze

JP

,
Christensen

R

,
Faber

J.

Cardiac natriuretic peptides in plasma increase after dietary induced weight loss in obesity

.
BMC Obes

2014

;
1

:
24

.
46

de Simone

G

,
Devereux

RB

,
Palmieri

V

,
Roman

MJ

,
Celentano

A

,
Welty

TK

,
Fabsitz

RR

,
Contaldo

F

,
Howard

BV.

Relation of insulin resistance to markers of preclinical cardiovascular disease: the Strong Heart Study

.

Nutr Metab Cardiovasc Dis

2003

**;
13**

**;
140**

**-14
7**

**.
47**

Ferrannini

G

**,
Hach**

T

**,
Crowe**

S

**,
Sanghvi**

A

**,
Hall**

KD

**,
Ferrannini**

E.

Energy balance after sodium-glucose cotransporter 2 inhibition

.
Diabetes Care

2015

;
38

:
1730

-173
5

.
48

Rajeev

SP

,
Cuthbertson

DJ

,
Wilding

JP.

Energy balance and metabolic changes with sodium-glucose co-transporter 2 inhibition

.
Diabetes Obes Metab

2016

;
18

:
125

-1

34

.

49

Bolinder

J

,

Ljunggren

O

,

Johansson

L

,

Wilding

J

,

Langkilde

AM

,

Sjostrom

CD

,

Sugg

J

,

Parikh

S.

Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin

.
Diabetes Obes Metab

2014

;
16

:
159

-1
69

.
50

Cefalu

WT

,
Leiter

LA

,
Yoon

KH

,
Arias

P

,
Niskanen

L

,

Xie

J

**,
Balis**

DA

**,
Canovatchel**

W

**,
Meininger**

G.

Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial

**.
Lancet**

2013

**;
382**

**:
941**

**-9
50**

**.
51**

Ridderstrale

M

**,
Andersen**

KR

,
Zeller

C

,
Kim

G

,
Woerle

HJ

,
Broedl

UC.

Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial

.
Lancet Diabetes Endocrinol

2014

;
2

;
691

–
700

.
52

Abraham

TM

,
Pedley

A

,
Massaro

JM

,
Hoffmann

U

,
Fox

CS.

Association between visceral and subcutaneous adipose depots and incident cardiovascular disease risk factors

.
Circulation

2015

;
132

:
1639

-16
47

.
53

Ferrannini

E

,
Ramos

SJ

,
Salsali

A

,
Tang

W

,
List

JF.

Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial

.
Diabetes Care

2010

;
33

:
2217

-22
24

.
54

Okamoto

A

,
Yokokawa

H

,
Sanada

H

,
Naito

T.

Changes in levels of biomarkers associated with adipocyte function and insulin and glucagon kinetics during treatment with dapagliflozin among obese type 2 diabetes mellitus patients

.
Drugs R D

2016

;
16

:
255

-2
61

.
55

Ferrannini

E

,
Muscelli

E

,
Frascerra

S

,

Baldi

S

**,
Mari**

A

**,
Heise**

T

**,
Broedl**

UC

**,
Woerle**

HJ.

Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients

**.
J Clin Invest**

2014

**;
124**

**;
499**

**-
508**

**.
56**

Mudaliar

S

,
Henry

RR

,
Boden

G

,
Smith

S

,
Chalamandaris

AG

,
Duchesne

D

,
Iqbal

N

,
List

J.

**Changes in insulin sensitivity and insulin secretion with the sodium glucose
cotransporter 2 inhibitor dapagliflozin**

.
Diabetes Technol Ther

2014

;

16

**:
137**

**-1
44**

**.
57**

Paternostro

G

**,
Pagano**

D

**,
Gnecchi-Ruscone**

T

**,
Bonser**

RS

**,
Camici**

PG.

Insulin resistance in patients with cardiac hypertrophy

**.
Cardiovasc Res**

1999

**;
42**

:

246

-2

53

.

© The Author(s) 2020. Published by Oxford University Press on behalf of the European Society of Cardiology.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.